Allergies News and Research

Latest Allergies News and Research

Majority of Missourians continue to favor nonprescription access to PSE-containing medicines

The Consumer Healthcare Products Association (CHPA) released today a recent poll that found a majority of Missourians -- by a margin of 16 percent -- continue to favor nonprescription access to safe and effective medicines containing pseudoephedrine (PSE), such as Advil Cold & Sinus, Allegra-D, Claritin-D, Mucinex-D, and Sudafed over a prescription mandate.

7 Mar 2012

Timely treatment with Berinert provides faster symptom relief for HAE patients

CSL Behring announced today that treatment with Berinert, C1 Esterase Inhibitor (Human) within six hours of the onset of an acute hereditary angioedema (HAE) attack provides faster symptom relief than later treatment, according to data presented at the 2012 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

7 Mar 2012

Rep. Sensenbrenner sends 'fact-finding letter' to White House science adviser about bird flu studies

"Representative Jim Sensenbrenner (R-Wis.), a former head of the House committees on science and the judiciary, and currently vice chair of the House Committee on Science, Space, and Technology, last week sent a 'fact-finding letter' to White House science adviser John Holdren, asking pointed questions about how the U.S. government has handled the controversy" surrounding two studies that showed how H5N1 bird flu virus could be manipulated to become transmissible among ferrets, a model for humans, "and questioning whether it should have funded the two flu studies," ScienceInsider reports.

6 Mar 2012

Merck announces results from AIT Phase III clinical study for ragweed allergy

Merck, known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen.

6 Mar 2012

Santarus fourth quarter total revenues increase 65% to $42.6M

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the three and 12 month periods ended December 31, 2011.

5 Mar 2012

Snoring toddlers may develop behavioural problems later: Study

A new study shows that babies and toddlers who snore, gasp for breath, or breathe with their mouth open while sleeping may be at a greater risk of behavioural problems all the way through second grade.

5 Mar 2012

Merck announces success of pill against ragweed allergy

Merck & Co. announced Monday that their experimental allergy tablet reduced allergic reactions to ragweed and helped patients use less medication to treat their symptoms.

5 Mar 2012

Meda announces positive results from three MP29-02 studies on allergic rhinitis

Meda announced today positive results of three studies of MP29-02 (tentatively called Dymista), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate.

5 Mar 2012

Study: Bioavailability similar among four subcutaneous IgG preparations

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route.

5 Mar 2012

Consensus across studies promises to enhance NIH-supported asthma clinical research

A consortium of federal agencies and nongovernmental organizations has published a report proposing a set of common measures and data-collection methods for use in asthma clinical research.

3 Mar 2012

New outcome measures may reduce disparities in children with asthma

Newly proposed asthma outcome measures will help standardize and improve results from the hundreds of millions of dollars the National Institutes of Health (NIH) spends annually to study asthma, according to the Merck Childhood Asthma Network, Inc. (MCAN), the nation's only organization focused solely on childhood asthma.

3 Mar 2012

Long-term data from Baxter's HyQ clinical study on PI

Baxter International Inc. today announced the presentation of additional long-term data supporting the clinical profile of HyQ, its investigational combination product for use in patients with primary immunodeficiencies.

From Baxter International Inc. 3 Mar 2012

A longer spring allergy season due to winter's warmer-than-average temperatures

While this winter's warmer-than-average temperatures were a nice contrast for people who suffered through to last year's many winter storms, many may now pay for the balmy temperatures with an earlier and longer spring allergy season. For some, symptoms such as runny nose, nasal congestion, sneezing, itchy eyes, ears and throat, wheezing and shortness of breath have already begun and may last into early summer.

2 Mar 2012

New HS44 molecule inhibits lung metastasis

One type of white blood cell, the Natural Killer T Cells, fights against infections and tumours by freeing cytokine proteins which activate the body's immune response and destroy infected or malignant cells. To do so they must receive an activation signal. Specific receptors located on their surface act as switches: they activate the lymphocyte in presence of an antigen, a molecule which triggers alarm signals.

2 Mar 2012

U.S. panel may re-evaluate bird flu research after scientists present new data about risks to humans

Speaking at the American Society for Microbiology's (ASM) Biodefense and Emerging Diseases Research meeting in Washington, D.C., on Wednesday, Ron Fouchier, the leader of the team at Erasmus Medical Center in the Netherlands that genetically altered the H5N1 bird flu virus, making it transmissible among ferrets and "touching off public fears of a pandemic, said that the virus he created was neither as contagious nor as dangerous as people had been led to believe, prompting the United States government to ask that the experiments be re-evaluated by a government advisory panel that recommended in December that certain details of the work be kept secret and not published," the New York Times reports.

1 Mar 2012

Parasitic worms could offer new treatment hope for MS patients

Parasitic worms could offer a new treatment hope for patients suffering from the autoimmune disease multiple sclerosis, scientists believe.

1 Mar 2012

Gluten-free, casein-free diet more effective in improving ASD behaviors and symptoms

A gluten-free, casein-free diet may lead to improvements in behavior and physiological symptoms in some children diagnosed with an autism spectrum disorder (ASD), according to researchers at Penn State. The research is the first to use survey data from parents to document the effectiveness of a gluten-free, casein-free diet on children with ASD.

1 Mar 2012

New research shows beneficial side effect of anti-allergy parasite

New research is showing a beneficial side effect of parasites for our health. Hygiene Hypothesis: As rates of allergy are reported to have tripled in the UK in the past decade, the scientific finger is pointing to an over-sanitised lifestyle making our immune responses overactive. Now, a team of biologists at the University of Edinburgh, led by Professor Rick Maizels, are investigating how parasitic worms could offer a cure for modern illnesses.

1 Mar 2012

WUSM to study children with weakened immune systems

Not all viruses make us sick. But which ones are friends and which ones are foes? Researchers at Washington University School of Medicine in St. Louis have received a five-year, $3.3 million grant to study children with weakened immune systems to identify the viruses that make children sick.

29 Feb 2012

Genome sequencing helps characterize S. aureus ST398-NM strain

Using genome sequencing and household surveillance, National Institutes of Health (NIH) scientists and their colleagues from Columbia University Medical Center and St. George's University of London have pieced together how a newly emerging type of Staphylococcus aureus bacteria has adapted to transmit more easily among humans.

29 Feb 2012